查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836233

慢性難治性痛風市場，按治療類別、按給藥途徑、按疾病負擔、按合併症情況、按護理環境、按配銷通路和按地區 - 行業分析、市場規模、市場佔有率和預測（2025 年至 2032 年）

Chronic Refractory Gout Market, By Therapy Class, By Route of Administration, By Disease Burden, By Comorbidity Profile, By Care Setting, By Distribution Channel, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 402 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年慢性難治性痛風市場規模價值 18.0425 億美元，2025 年至 2032 年的複合年成長率為 10.23%。

慢性難治性痛風是一種嚴重的痛風類型，患者對標準降尿酸療法反應不佳或無法耐受。其特徵是持續高尿酸水平、頻繁的疼痛發作以及痛風石形成，痛風石會損害關節和周圍組織。這種疾病通常需要先進的治療方法，例如基於尿酸酶的療法或生物製劑，以及對合併症的全面管理，以減少併發症並改善生活品質。

慢性難治性痛風市場-市場動態

全球痛風負擔加重，推動市場需求

全球痛風負擔日益加重，推動了對先進治療方案的需求。 2020年，全球估計有5,580萬人患有痛風。肥胖和腎功能障礙是導致痛風致殘的主要原因，其中高體重指數佔痛風致殘壽命年（YLD）的34.3%，腎功能障礙佔11.8%。然而，這些合併症的漏診往往會延誤適當的治療。

美國疾病管制與預防中心 (CDC) 報告稱，超過七分之一的美國成年人患有慢性腎臟病。積極的一面是，針對肥胖的生活方式介入可以顯著降低痛風的嚴重程度和進展。此外，改善痛風患者的慢性腎臟病 (CKD) 檢測可以改善治療效果，並有助於解決導致難治性痛風的關鍵潛在因素之一。

慢性難治性痛風市場-細分分析：

全球慢性難治性痛風市場根據治療類別、給藥途徑、疾病負擔、合併症概況、推進力、配銷通路和地區進行細分。

根據治療類別，市場分為四類：尿酸酶療法、IL-1抑制劑、輔助抗發炎藥物和新一代小分子藥物。預計尿酸酶療法將在預測期內佔據主要市場佔有率。這種主導地位源於其獨特的功效，即快速有效地降低對常規治療無效患者的血清尿酸水平。

根據合併症情況，市場分為兩類：腎功能損害和心血管/代謝疾病。其中，腎功能損害預計將佔據主要市場佔有率。慢性腎臟病是痛風患者的常見併發症，限制了傳統降尿酸藥物的使用，並增加了對尿酸酶類藥物等先進療法的依賴。腎功能損害是治療的最大挑戰，推動了該患者群體對專業有效的治療方案的需求日益增強。

慢性難治性痛風市場－地理洞察

北美癌症切片市場佔據全球主導地位，由於疾病負擔高且醫療基礎設施完善，慢性難治性痛風領域也呈現類似的趨勢。根據美國疾病管制與預防中心 (CDC) 的數據，美國近 920 萬成年人患有痛風，約佔成年人口的 3.9%。

其中相當一部分病例發展為慢性和難治性疾病，推動了對聚乙二醇重組尿酸酶等先進療法的需求。美國食品藥物管理局 (FDA) 已優先批准生物製劑和新型降尿酸藥物，以滿足難治性病例中尚未滿足的需求。在歐洲，痛風的盛行率也引人注目，英國國家醫療服務體系 (NHS) 報告稱，過去十年痛風相關住院人數急劇上升。同時，在亞太地區，日本厚生勞動省將痛風列為與生活方式疾病相關的日益嚴重的問題，這進一步擴大了治療需求。

慢性難治性痛風市場-競爭格局：

不受控制的痛風病例日益增多，促使各公司改善治療策略。競爭對手正專注於開發安全性更高、療效更持久的生物製劑和基於尿酸酶的療法。許多公司正在探索與免疫調節劑的聯合療法，以減少抗體形成並提高療效。與研究機構、專科診所和付款方的合作旨在擴大患者的治療可及性。同時，各公司正在投資患者支援計畫、輸液服務和數位監測工具，以增強患者依從性並改善長期治療效果。

目錄

第1章：慢性難治性痛風市場概述

  • 研究範圍
  • 市場估計年限

第 2 章：執行摘要

  • 市場片段
    • 慢性難治性痛風市場片段（依治療類別）
    • 慢性難治性痛風市場依給藥途徑分類
    • 慢性難治性痛風市場片段（依疾病負擔）
    • 慢性難治性痛風市場片段（依合併症概況）
    • 慢性難治性痛風市場片段（依護理環境）
    • 慢性難治性痛風市場片段（依配銷通路）
    • 慢性難治性痛風市場（依國家）
    • 慢性難治性痛風市場（按地區）
  • 競爭洞察

第3章：慢性難治性痛風關鍵市場趨勢

  • 慢性難治性痛風市場促進因素
    • 市場促進因素的影響分析
  • 慢性難治性痛風市場限制
    • 市場限制的影響分析
  • 慢性難治性痛風市場機遇
  • 慢性難治性痛風市場未來趨勢

第4章：慢性難治性痛風產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：慢性難治性痛風市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：慢性難治性痛風市場格局

  • 2023年慢性難治性痛風市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：慢性難治性痛風市場－依治療類型

  • 概述
    • 按治療類別分類的細分佔有率分析
      • 尿酸酶療法
      • IL-1抑制劑
      • 輔助抗發炎藥
      • 新一代小分子

第 8 章：慢性難治性痛風市場 - 依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 靜脈
    • 皮下
    • 口服

慢性難治性痛風市場 - 按疾病負擔

  • 概述
    • 按疾病負擔分類的細分佔有率分析
    • 痛風石性CRG
    • 頻繁爆發
    • 侵蝕/結構損壞

第9章：慢性難治性痛風市場－依合併症分類

  • 概述
    • 依合併症狀況分析細分佔有率
    • 腎功能不全
    • 心血管/代謝疾病

第 10 章：慢性難治性痛風市場 - 按護理環境

  • 概述
    • 按護理環境分類的細分佔有率分析
    • 醫院
    • 專科風濕病診所
    • 點滴中心

第 11 章：慢性難治性痛風市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 專業藥房
    • 零售

第 12 章：慢性難治性痛風市場 - 按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美慢性難治性痛風主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（按治療類別）
    • 北美市場規模及預測（按給藥途徑）
    • 北美市場規模及預測（按疾病負擔）
    • 北美市場規模與預測，按合併症概況
    • 北美市場規模與預測，按護理環境
    • 北美市場規模及預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲慢性難治性痛風主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（依治療類別）
    • 歐洲市場規模及預測（依管理途徑）
    • 歐洲市場規模及預測（依疾病負擔）
    • 歐洲市場規模與預測，按合併症概況
    • 歐洲市場規模與預測，按護理環境
    • 歐洲市場規模及預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區慢性難治性痛風主要製造商
    • 亞太市場規模及預測（按國家/地區）
    • 亞太市場規模及預測（依治療類別）
    • 亞太地區市場規模及預測（依給藥途徑）
    • 亞太市場規模及預測（依疾病負擔）
    • 亞太市場規模及預測（依合併症情形）
    • 亞太市場規模及預測（依護理環境）
    • 亞太市場規模及預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲慢性難治性痛風主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依治療類別）
    • 拉丁美洲市場規模及預測（按給藥途徑）
    • 拉丁美洲市場規模及預測（按疾病負擔）
    • 拉丁美洲市場規模及預測（依合併症情形）
    • 拉丁美洲市場規模及預測（按護理環境）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲慢性難治性痛風主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（按治療類別）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按疾病負擔）
    • 中東及非洲市場規模及預測（依合併症情形）
    • 中東和非洲市場規模及預測（按護理環境）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 13 章：關鍵供應商分析-慢性難治性痛風產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • LG Chem
    • Jiangsu Hengrui Pharmaceuticals
    • JW Group / Simcere
    • Selecta / Cartesian Therapeutics
    • Sobi (Swedish Orphan Biovitrum)
    • Teijin America
    • InventisBio
    • Arthrosi Therapeutics
    • Shanton Pharma
    • Atom Bioscience
    • Horizon Therapeutics / Amgen
    • Nippon Chemiphar
    • Protalix BioTherapeutics
    • Arrowhead Pharmaceuticals
    • Hinova Pharmaceuticals
    • TaiwanJ Pharmaceuticals
    • Cartesian Therapeutics
    • Amgen
    • Takeda Pharmaceutical Company
    • AstraZeneca
    • Others

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5677

Chronic refractory gout market size was valued at US$ 1,804.25 Million in 2024, expanding at a CAGR of 10.23% from 2025 to 2032.

Chronic refractory gout is a severe form of gout in which patients do not respond adequately to standard urate-lowering therapies or cannot tolerate them. It is characterized by persistently high uric acid levels, frequent painful flares, and tophi formation that can damage joints and surrounding tissues. This condition often requires advanced treatments, such as uricase-based therapies or biologics, along with comprehensive management of comorbidities to reduce complications and improve quality of life.

Chronic Refractory Gout Market- Market Dynamics

Increasing burden of gouts across the globe to propel market demand

The rising global burden of gout is driving demand for advanced treatment options. In 2020, an estimated 55.8 million people worldwide were living with gout. Obesity and kidney dysfunction are major contributors to disability from the disease, with high body mass index accounting for 34.3% of years lived with disability (YLDs) due to gout, and kidney dysfunction contributing 11.8%. However, underdiagnosis of these comorbidities often delays appropriate treatment.

In the United States, the Centers for Disease Control and Prevention (CDC) reports that more than 1 in 7 adults have chronic kidney disease. On the positive side, lifestyle interventions targeting obesity can significantly reduce gout severity and progression. Additionally, improving chronic kidney disease (CKD) detection in gout patients could enhance treatment outcomes and help address one of the key underlying drivers of refractory cases.

Chronic Refractory Gout Market- Segmentation Analysis:

The Global Chronic Refractory Gout Market is segmented on the basis of Therapy Class, Route of Administration, Disease Burden, Comorbidity Profile, Propulsion, Distribution Channel, and Region.

The market is divided into four categories based on Therapy Class: uricase therapies, IL-1 inhibitors, adjunct anti-inflammatories, and next-generation small molecules. The uricase therapies segment is expected to hold the major market share during the forecast period. This dominance is driven by their unique ability to rapidly and effectively lower serum uric acid levels in patients unresponsive to conventional treatments.

The market is divided into two categories based on Comorbidity Profile: renal impairment and cardiovascular/metabolic conditions. Among these, the renal impairment segment is expected to capture the major market share. Chronic kidney disease is a frequent complication in gout patients, limiting the use of traditional urate-lowering drugs and creating higher reliance on advanced therapies like uricase-based treatments. Renal impairment poses the greatest therapeutic challenge, driving stronger demand for specialized and effective treatment options in this patient group.

Chronic Refractory Gout Market- Geographical Insights

North America cancer biopsy market dominated the global market, and a similar trend is observed in the chronic refractory gout segment due to high disease burden and strong healthcare infrastructure. According to the U.S. Centers for Disease Control and Prevention (CDC), nearly 9.2 million adults in the United States suffer from gout, representing about 3.9% of the adult population.

A significant proportion of these cases develop into chronic and treatment-resistant forms, driving the demand for advanced therapies such as pegloticase. The U.S. Food and Drug Administration (FDA) has prioritized approvals of biologics and novel urate-lowering drugs to address unmet needs in refractory cases. In Europe, the prevalence is also notable, with the UK's National Health Service (NHS) reporting a sharp rise in gout-related hospital admissions over the past decade. Meanwhile, in Asia Pacific, Japan's Ministry of Health and Welfare identifies gout as a growing concern linked to lifestyle diseases, further expanding treatment demand.

Chronic Refractory Gout Market- Competitive Landscape:

Rising prevalence of uncontrolled gout cases is encouraging companies to refine treatment strategies. Competitors are focusing on developing biologics and uricase-based therapies with improved safety and longer durability of response. Many are exploring combination regimens with immunomodulators to reduce antibody formation and enhance effectiveness. Partnerships with research institutes, specialty clinics, and payers aim to expand patient access. In parallel, firms are investing in patient-support programs, infusion services, and digital monitoring tools to strengthen adherence and improve long-term treatment outcomes.

Recent Development:

In March 2025, Shanton Pharma announced positive Phase 2b results for SAP-001 in refractory gout patients, showing nearly 100% target achievement versus 10% on conventional therapy, with sustained effects, strong efficacy, and excellent safety across six months of treatment.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHRONIC REFRACTORY GOUT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • LG Chem
  • Jiangsu Hengrui Pharmaceuticals
  • JW Group / Simcere
  • Selecta / Cartesian Therapeutics
  • Sobi (Swedish Orphan Biovitrum)
  • Teijin America
  • InventisBio
  • Arthrosi Therapeutics
  • Shanton Pharma
  • Atom Bioscience
  • Horizon Therapeutics / Amgen
  • Nippon Chemiphar
  • Protalix BioTherapeutics
  • Arrowhead Pharmaceuticals
  • Hinova Pharmaceuticals
  • TaiwanJ Pharmaceuticals
  • Cartesian Therapeutics
  • Amgen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • Others

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY THERAPY CLASS- MARKET ANALYSIS, 2019 - 2032

  • Uricase Therapies
  • IL-1 inhibitors
  • Adjunct Anti-inflammatories
  • Next-generation Small Molecules

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Subcutaneous
  • Oral

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY DISEASE BURDEN- MARKET ANALYSIS, 2019 - 2032

  • Tophaceous CRG
  • Frequent Flares
  • Erosive/structural damage

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY COMORBIDITY PROFILE- MARKET ANALYSIS, 2019 - 2032

  • Renal Impairment
  • Cardiovascular/Metabolic Conditions

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY CARE SETTING- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Rheumatology Clinics
  • Infusion Centers

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Chronic Refractory Gout Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Chronic Refractory Gout Market Snippet by Therapy Class
    • 2.1.2. Chronic Refractory Gout Market Snippet by Route of Administration
    • 2.1.3. Chronic Refractory Gout Market Snippet by Disease Burden
    • 2.1.4. Chronic Refractory Gout Market Snippet by Comorbidity Profile
    • 2.1.5. Chronic Refractory Gout Market Snippet by Care Setting
    • 2.1.6. Chronic Refractory Gout Market Snippet by Distribution Channel
    • 2.1.7. Chronic Refractory Gout Market Snippet by Country
    • 2.1.8. Chronic Refractory Gout Market Snippet by Region
  • 2.2. Competitive Insights

3. Chronic Refractory Gout Key Market Trends

  • 3.1. Chronic Refractory Gout Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Chronic Refractory Gout Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Chronic Refractory Gout Market Opportunities
  • 3.4. Chronic Refractory Gout Market Future Trends

4. Chronic Refractory Gout Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Chronic Refractory Gout Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Chronic Refractory Gout Market Landscape

  • 6.1. Chronic Refractory Gout Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Chronic Refractory Gout Market - By Therapy Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy Class, 2023 & 2032 (%)
      • 7.1.1.1. Uricase Therapies
      • 7.1.1.2. IL-1 Inhibitors
      • 7.1.1.3. Adjunct anti-inflammatories
      • 7.1.1.4. Next-generation Small Molecules

8. Chronic Refractory Gout Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Intravenous
    • 8.1.3. Subcutaneous
    • 8.1.4. Oral

Chronic Refractory Gout Market - By Disease Burden

  • 8.2. Overview
    • 8.2.1. Segment Share Analysis, By Disease Burden, 2023 & 2032 (%)
    • 8.2.2. Tophaceous CRG
    • 8.2.3. Frequent Flares
    • 8.2.4. Erosive/Structural Damage

9. Chronic Refractory Gout Market - By Comorbidity Profile

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Comorbidity Profile, 2023 & 2032 (%)
    • 9.1.2. Renal Impairment
    • 9.1.3. Cardiovascular/Metabolic Conditions

10. Chronic Refractory Gout Market - By Care Setting

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Care Setting, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Rheumatology Clinics
    • 10.1.4. Infusion Centers

11. Chronic Refractory Gout Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital Pharmacies
    • 11.1.3. Specialty Pharmacies
    • 11.1.4. Retail

12. Chronic Refractory Gout Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Chronic Refractory Gout Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.2.9. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. U.S.
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. U.S. Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.2.10.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.5. U.S. Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.2.10.6. U.S. Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.2.10.7. U.S. Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.2.10.8. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.10.9.
    • 12.2.11. Canada
      • 12.2.11.1. Overview
      • 12.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.11.3. Canada Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.2.11.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.11.5. Canada Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.2.11.6. Canada Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.2.11.7. Canada Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.2.11.8. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.11.9.
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Chronic Refractory Gout Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.3.9. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Germany
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Germany Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Germany Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Germany Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Germany Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.10.8. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. Italy
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. Italy Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.5. Italy Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.11.6. Italy Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.11.7. Italy Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.11.8. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. United Kingdom
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. United Kingdom Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.12.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.5. United Kingdom Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.12.6. United Kingdom Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.12.7. United Kingdom Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.12.8. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. France
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. France Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.13.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. France Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.13.6. France Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.13.7. France Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.13.8. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Russia
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Russia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Russia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Russia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Russia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.14.7. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Netherlands
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Netherlands Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Netherlands Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Netherlands Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Netherlands Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Sweden
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Sweden Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Sweden Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Sweden Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Sweden Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.2. Poland Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.18.8. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Chronic Refractory Gout Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.4.9. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.10.8. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. China
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. China Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.11.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.5. China Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.11.6. China Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.11.7. China Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.11.8. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. Japan
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. Japan Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.12.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.5. Japan Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.12.6. Japan Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.12.7. Japan Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.12.8. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. South Korea
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. South Korea Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.13.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.5. South Korea Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.13.6. South Korea Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.13.7. South Korea Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.13.8. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Australia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Australia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Australia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Australia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Australia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.14.8. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.15.8. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Indonesia
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Indonesia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Indonesia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Indonesia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Indonesia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.16.8. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Philippines
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Philippines Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Philippines Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Philippines Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Philippines Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.17.8. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.18. Rest of APAC
      • 12.4.18.1. Overview
      • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.18.3. Rest of APAC Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.18.5. Rest of APAC Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.18.6. Rest of APAC Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.18.7. Rest of APAC Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.18.8. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Chronic Refractory Gout Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.5.9. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Brazil
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Brazil Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Brazil Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Brazil Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Brazil Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.10.8. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Mexico
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Mexico Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Mexico Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Mexico Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Mexico Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.11.8. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Argentina
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Argentina Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Argentina Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Argentina Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Argentina Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.12.8. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Colombia
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Colombia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Colombia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Colombia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Colombia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.13.8. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.14. Rest of LATAM
      • 12.5.14.1. Overview
      • 12.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.14.3. Rest of LATAM Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.14.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.14.5. Rest of LATAM Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.14.6. Rest of LATAM Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.14.7. Rest of LATAM Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.14.8. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Chronic Refractory Gout Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.6.9. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. Saudi Arabia
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. Saudi Arabia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.10.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.5. Saudi Arabia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.10.6. Saudi Arabia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.10.7. Saudi Arabia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.10.8. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. United Arab Emirates
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. United Arab Emirates Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.11.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.5. United Arab Emirates Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.11.6. United Arab Emirates Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.11.7. United Arab Emirates Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.11.8. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Israel
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Israel Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Israel Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Israel Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Israel Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.12.8. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Turkey
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Turkey Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Turkey Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Turkey Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Turkey Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.13.8. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Algeria
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Algeria Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Algeria Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Algeria Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Algeria Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.14.8. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Egypt
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Egypt Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Egypt Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Egypt Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Egypt Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.15.8. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.16. Rest of MEA
      • 12.6.16.1. Overview
      • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.16.3. Rest of MEA Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.16.5. Rest of MEA Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.16.6. Rest of MEA Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.16.7. Rest of MEA Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.16.8. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Chronic Refractory Gout Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. LG Chem
    • 13.2.2. Jiangsu Hengrui Pharmaceuticals
    • 13.2.3. JW Group / Simcere
    • 13.2.4. Selecta / Cartesian Therapeutics
    • 13.2.5. Sobi (Swedish Orphan Biovitrum)
    • 13.2.6. Teijin America
    • 13.2.7. InventisBio
    • 13.2.8. Arthrosi Therapeutics
    • 13.2.9. Shanton Pharma
    • 13.2.10. Atom Bioscience
    • 13.2.11. Horizon Therapeutics / Amgen
    • 13.2.12. Nippon Chemiphar
    • 13.2.13. Protalix BioTherapeutics
    • 13.2.14. Arrowhead Pharmaceuticals
    • 13.2.15. Hinova Pharmaceuticals
    • 13.2.16. TaiwanJ Pharmaceuticals
    • 13.2.17. Cartesian Therapeutics
    • 13.2.18. Amgen
    • 13.2.19. Takeda Pharmaceutical Company
    • 13.2.20. AstraZeneca
    • 13.2.21. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us